{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma&page=11", "query": { "condition": "B-cell Non-Hodgkin Lymphoma", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 2216, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non-Hodgkin+Lymphoma&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T10:49:11.010Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06723457", "title": "Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder", "Refractory B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Reem Karmali", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2025-07-25", "completion_date": "2029-02-18", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06723457" }, { "nct_id": "NCT02767934", "title": "Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "Minimal Residual Disease", "Recurrent Acute Lymphoblastic Leukemia", "T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-01-13", "completion_date": "2019-12-17", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02767934" }, { "nct_id": "NCT03698552", "title": "ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blasts 5 Percent or More of Bone Marrow Nucleated Cells", "CD22 Positive", "Philadelphia Chromosome Positive", "Recurrent B Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "ADCT-602", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2018-08-24", "completion_date": "2025-11-06", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 2, "location_summary": "Monrovia, California • Houston, Texas", "locations": [ { "city": "Monrovia", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03698552" }, { "nct_id": "NCT00317785", "title": "Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2005-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-05-07", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00317785" }, { "nct_id": "NCT03365791", "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Gastric Adenocarcinoma", "Esophageal Adenocarcinoma", "Castration Resistant Prostate Adenocarcinoma", "Soft Tissue Sarcoma", "Ovarian Adenocarcinoma", "Advanced Well-differentiated Neuroendocrine Tumors", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" }, { "name": "LAG525", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2018-01-24", "completion_date": "2020-09-17", "has_results": true, "last_update_posted_date": "2022-05-27", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 20, "location_summary": "San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03365791" }, { "nct_id": "NCT00211276", "title": "A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "ONTAK (denileukin diftitox)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2005-03", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2012-03-14", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 12, "location_summary": "Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00211276" }, { "nct_id": "NCT02760485", "title": "A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "itacitinib", "type": "DRUG" }, { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2016-12-29", "completion_date": "2022-06-06", "has_results": true, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Duarte, California • Long Beach, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760485" }, { "nct_id": "NCT05460533", "title": "A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Day to 25 Years" }, "enrollment_count": 30, "start_date": "2022-07-12", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 6, "location_summary": "Los Angeles, California • Stanford, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05460533" }, { "nct_id": "NCT07226843", "title": "A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin's", "Lymphoma, Diffuse Large B-Cell", "Follicular Lymphoma" ], "interventions": [ { "name": "LY4584180", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2026-04-17", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226843" }, { "nct_id": "NCT01148108", "title": "Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "B Cell Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Canfosfamide HCl for injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2010-06", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2013-03-15", "last_synced_at": "2026-10-14T10:49:11.010Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148108" } ] }